Welcome to CDC stacks | Catalog of immunological and microbiological reference reagents - 7669 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Catalog of immunological and microbiological reference reagents
  • Published Date:
    Revised edition 1973
Filetype[PDF-29.94 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Catalog of immunological and microbiological reference reagents
Details:
  • Corporate Authors:
    Center for Disease Control. Laboratory Division. Scientific Resources Branch. Biological Reagents Section.
  • Description:
    Prepared by the Biological Reagents Section and distributed for reference use by the Scientific Resources Branch, Laboratory Division, Center for Disease Control.

  • Document Type:
    Book
  • Collection(s):
    Stephen B. Thacker CDC Library collection
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. International influenza laboratory capacity review. June 2012: Version 3
    Corporate Author:
    Association of Public Health Laboratories (U.S.); Centers for Disease Control and Prevention (U.S.);
    Published:
    June 2012
    Description:
    The CDC-APHL International Influenza Laboratory Capacity Review Tool (IILCRT) is a data gathering tool to assess laboratory capabilities and capacities, with an emphasis on influenza diagnostics. The information collected from the tool can be used to...
    File Type:
    Filetype[PDF - 1.50 MB]
  2. National Center for Infectious Diseases (CVC)
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.). Management Analysis and Services Office.
    Published:
    7/28/08
    Series:
    MASO CDC organization ; CVC
    Description:
    Plans, directs, and coordinates a national program to improve the identification, investigations, diagnosis, prevention, and control of infectious diseases. In carrying out the mission, the Center: (1) provides leadership in investigation and diagnos...
    File Type:
    Filetype[PDF - 231.39 KB]
  3. Gonococcal isolate surveillance program (GISP) protocol
    Personal Author:
    Kirkcaldy, Robert D.; Torrone, Elizabeth; Papp, John R.;
    Corporate Author:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of STD Prevention.
    Published:
    May 2016
    Description:
    The treatment and control of Neisseria gonorrhoeae infections have been complicated by the organism’s ability to acquire antimicrobial resistance. The increasing prevalence of strains with plasmid-mediated resistance to penicillin (PPNG) prompted t...
    File Type:
    Filetype[PDF - 781.02 KB]
  4. NIOSH skin notation (SK) profile; glutaraldehyde [CAS No. 111-30-8]
    Corporate Author:
    National Institute for Occupational Safety and Health, Education and Information Division.
    Published:
    April 2011
    Series:
    DHHS publication ; no. (NIOSH) 2011-149
    Description:
    This Skin Notation Profile provides the SK assignment and supportive data for glutaraldehyde (CAS No. 111-30-8). In particular, this document evaluates and summarizes the literature describing the substance's hazard potential and its assessment accor...
    File Type:
    Filetype[PDF - 684.61 KB]
  5. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein
    Personal Author:
    Tian, Daiyin; Battles, Michael B.; Moin, Syed M.; Chen, Man; Modjarrad, Kayvon; Kumar, Azad; Kanekiyo, Masaru; Graepel, Kevin W.; Taher, Noor M.; Hotard, Anne L.; Moore, Martin L.; Zhao, Min; Zheng, Zi-Zheng; Xia, Ning-Shao; McLellan, Jason S.; Graham, Barney S.;
    Published:
    Nov 30 2017
    Source:
    Nat Commun. 8.
    Description:
    A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab...
    File Type:
    Filetype[PDF - 2.06 MB]